Naratriptan
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Naratriptan: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Naratriptan is a selective 5-HT1B/1D receptor agonist originally used for the acute treatment of migraine. The TxGNN model predicts it may be effective for migraine with brainstem aura, but there are currently no registered clinical trials, and the 19 publications found concern migraine in general rather than this subtype specifically.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine disorder (the Singapore licence record contains no approved indication text, so this comes from the knowledge-graph indication data) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, naratriptan is a selective 5-HT1B/1D agonist (a triptan). Its efficacy in acute migraine is established, and mechanistically it may be applicable to migraine with brainstem aura.
Migraine with brainstem aura is a migraine subtype that shares trigeminovascular pathophysiology with common migraine, so efficacy is biologically plausible. The literature found covers acute treatment guidelines, naratriptan versus sumatriptan, prodrome prevention, menstrual migraine and paediatric use. None of it studies the brainstem aura subtype specifically.
There is also a safety question. Triptans have historically been used cautiously in aura subtypes with brainstem or hemiplegic features because of theoretical vasoconstriction concerns. This needs explicit review before any further development.
The other nine predictions (for example atrophoderma vermiculata, amenorrhea, sciatic neuropathy, dysthymic disorder and several hair disorders) have no trials or literature and no established mechanistic link. They are graph-based predictions only, so this report focuses on the top-ranked indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The table lists the most relevant publications, prioritising RCTs, then reviews. All concern migraine broadly, not brainstem aura specifically.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10972634 | 2000 | RCT | Clinical Therapeutics | Randomised, double-blind crossover comparing naratriptan and sumatriptan for headache recurrence in recurrence-prone migraine patients |
| 10961768 | 2000 | RCT | Cephalalgia | Naratriptan given during the prodrome to prevent migraine headache |
| 11264684 | 2001 | Randomised, placebo-controlled (type not formally classified) | Headache | Naratriptan 1 mg and 2.5 mg twice daily versus placebo as short-term prophylaxis of menstrually associated migraine |
| 25600718 | 2015 | Review | Headache | American Headache Society evidence assessment of acute migraine pharmacotherapies |
| 14511276 | 2003 | Review | Headache | Managing intractable migraine with naratriptan |
| 25100506 | 2014 | Review | Expert Opinion on Pharmacotherapy | Menstrual migraine: hormonal causes, prophylaxis and treatment |
| 21028917 | 2010 | Review | Paediatric Drugs | Use of triptans for paediatric migraine |
| 25841032 | 2015 | Not classified | Neurology | Sumatriptan was less effective in migraine with aura than without aura |
| 15926020 | 2005 | Open pilot study | Neurological Sciences | Naratriptan as short-term prophylaxis of pure menstrual migraine |
| 23877022 | 2014 | Case report | Brain & Development | Naratriptan improved intractable migraine-like headaches in a patient with Sturge-Weber syndrome and prior cerebral infarction |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14787P | Naratriptan Film-Coated Tablets 2.5 mg (Chanelle Medical Unlimited Company) | Film-coated tablet (oral) | Not stated in the licence record |
Safety Considerations
- Contraindication signals (knowledge-graph data, not label text): The drug is linked to contraindications in cardiovascular and cerebrovascular conditions, including hypertension, coronary artery disease, myocardial infarction, myocardial ischaemia, Prinzmetal angina, stroke, transient ischaemic attack, cerebral infarction, vertebrobasilar insufficiency, and peripheral vascular disease. It is also linked to liver failure, diabetes mellitus, diabetic ketoacidosis, obesity, hemoglobinopathy, and familial or sporadic hemiplegic migraine.
- Relevance to the new indication: Vertebrobasilar insufficiency and hemiplegic migraine are closely related to brainstem aura. This reinforces the vasoconstriction concern noted above.
- Drug Interactions: 39 interactions were identified. Major-level interactions include:
- serotonergic and anorectic agents: lorcaserin, fenfluramine, dexfenfluramine, sibutramine
- 5-HT3 antagonists: ondansetron, granisetron, dolasetron, palonosetron
- methylene blue
Moderate-level interactions include morphine (including liposomal morphine). Several others are of unknown severity, including omeprazole, lansoprazole, pantoprazole, ranitidine, clarithromycin, bupropion, prednisone, budesonide and promethazine. Many of the major interactions relate to a possible additive serotonergic effect.
- Package insert warnings and contraindications could not be obtained. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but it is model-based only. There are no clinical trials and no literature specific to brainstem aura. The evidence is general migraine data, and the subtype carries a theoretical vasoconstriction safety concern that is reflected in the knowledge-graph contraindications (vertebrobasilar insufficiency, hemiplegic migraine). The indication is best treated as a research question until these gaps are resolved.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (a blocking gap for safety screening)
- Detailed mechanism of action data (for example from DrugBank)
- A focused review of triptan safety and efficacy in brainstem aura and hemiplegic migraine
- Literature or trials specific to migraine with brainstem aura
- A confirmed approved indication text for the Singapore licence SIN14787P
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.